TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05327816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.
Study: NCT06207955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Arthrocentesis
Description: TMJ Arthrocentesis By Saline
Study: NCT04593381

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.
Study: NCT05327816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV preF-based Vaccine
Description: RSV preF-based vaccine will be administered as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as intramuscular injection.
Study: NCT05308706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8 weeks of home based use.
Description: Use of the devices for an 8 week study period. Devices are preset to follow a scheduled activation pattern during the day.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 8 weeks of home based use.
Description: Use of the devices for an 8 week study period. Devices are preset to follow a scheduled activation pattern during the day.
Study: NCT05059678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials and attend videoconference sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05358691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: To evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in Stage III Non-Small Cell Lung Cancer participants

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: To evaluate the safety and preliminary efficacy of AN0025 in combination with chemoradiation + consolidation durvalumab in Stage III Non-Small Cell Lung Cancer participants
Study: NCT05027035

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical plication or nocturnal non-invasive ventilation
Description: 10 participants for surgical plication and 10 participants for nocturnal non-invasive ventilation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgical plication or nocturnal non-invasive ventilation
Description: 10 participants for surgical plication and 10 participants for nocturnal non-invasive ventilation.
Study: NCT05527262

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Queen Square Upper Limb Neurorehabilitation Programme
Description: A timetable will be implemented including a minimum of 45 hours of active time on task over 3 weeks 5-days a week (first and last day will involve the assessment procedures) (timetabled, 90-hours). Our unpublished in-service audits suggest that this equates to 45-60 hours of active upper limb training. The remainder of the time is spent on rest (in-session, between-session), cardiovascular fitness, and education (promoting self-efficacy). The programme is staffed with a 1:1 staff/patient ratio (4 physiotherapists, 4 occupational therapists, 4 rehabilitation assistants for 12 patients at any one time). Participants in this trial will receive two daily sessions each of physiotherapy and occupational therapy, supplemented with tailored, individualised interventions delivered by rehabilitation assistants either singly or in groups.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immersive gaming therapy
Description: The treatment group will receive a minimum of 45 hours of active time on task over 3 weeks, 5 days a week (first and last day will involve the assessment procedures) to complete arm, hand and finger training (overseen by a physiotherapist). Patients will engage with MindPod Dolphin (shoulder/elbow) and other interfaces (hand/fingers) in a customised immersive game-based platform set.
Study: NCT05526469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: patients in this group will receive ultrasound guided single shot serratus anterior plane block for pain control intra and postoperative

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane blocks
Description: patients in this group will receive ultrasound guided single shot erector spinae plane block for pain control intra and postoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Patients in both group will receive 0.5 ml/kg bupivacaine 0.25% injected locally in the muscle plane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Injectable Solution
Description: Patients in both group will receive 0.5 ml/kg bupivacaine 0.25% injected locally in the muscle plane
Study: NCT04869397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Wharton's jelly-MSCs (WJ-MSC)
Description: The product is provided cryopreserved by NextCell Pharma. The cells are frozen in cryobags at a concentration of 2 × 107 cells/ml in 5% Human Serum Albumin (HSA) and 10% dimethylsulfoxide (DMSO). One cryobag contains one dose. The bags are frozen in a controlled rate freezer and directly transferred to -190 ºC for storage until the time of infusion.~Cryobags are thawed at bedside and diluted in 100 ml of saline prior to administration. Cells will be delivered at a rate of 5 million cells per minute over a total of 20 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium chloride buffer supplemented with 5% HSA and 10% DMSO same volume and mode of administration as treatment group
Study: NCT05667103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embotrap stent retriever
Description: Embotrap has a novel design of an open outer cage for clot capture and a closed inner channel for clot stabilization, with great thrombus fixation and anti-escape ability, to improve the successful recanalization rate and good prognosis of patients.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Solitaire FR, Trevo stent retriever without inner channel
Description: Other stent retriever without inner channel, such as Solitaire FR, Trevo, and other stent retrievers approved by FDA or NMPA.
Study: NCT06190964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative medicine
Description: Acupuncture; touch/movement techniques (for example, qigong, reflexology, shiatsu) and/or mind-body medicine (for example, relaxation and breathing exercises)
Study: NCT06415149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High power short duration ablation with 50 W
Description: Group 1 (n=95): pulmonary vein isolation for treatment of atrial fibrillation was performed with power of 50 watts in Ia subgroup (n=55) AI (ablation index) was 400-450 arbitrary units (au) for the posterior wall and 500-550 au for the anterior wall, in Ib (n=40) AI was 400-450 au for the posterior wall and 450-500 au for the anterior wall.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High power short duration ablation with 45 W
Description: Group 2 (n=90): Pulmonary vein islolation was performed at a power of 45 watts, in IIa subgroup (n=50) with target AI of 400-450 au for the posterior wall and 500-550 au for the anterior wall in IIb (n=40) AI of 400-450 au for the posterior wall and 450-500 au for the anterior wall.
Study: NCT05521815

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coma arousal therapy
Description: early coma arousal therapy program in addition to selected physical therapy program (positioning, breathing exercise, passive movement of the four limbs).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Selected physiotherapy program
Description: selected physiotherapy program only (positioning, breathing exercise, passive movement of the four limbs).
Study: NCT05670730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOC 1044
Description: AOC 1044 will be administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOC 1044
Description: AOC 1044 will be administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via intravenous (IV) infusion.
Study: NCT06533566

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: patients will be placed in the lateral decubitus position. The ESP block is usually performed at the level of fourth transvers process. The ultrasound probe should be placed in a cephalo-caudal orientation over the midline of the back at the desired level.Under aseptic conditions, the block needle will be inserted in plane at an angle of 30-40° in cranial-to-caudal direction until the tip contacted the T4 transverse process at erector spinae plane. After hydro-dissection with 2-3 mL of isotonic saline solution to confirm the correct needle tip position and after negative aspiration to prevent intra vascular injection or position, (20 ml) of plain bupivacaine 0.25% will be injected deep to the erector spinae muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local wound infiltration
Description: after the surgeon complete the surgery and insert the surgical drains (pectoral and axillary drains) we will inject 20ml of plain bupivacaine 0.25% in each surgical drain, the drains will be clamped for 20 minutes then declamped.
Study: NCT04217603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) device
Description: Use of a CPAP during a 6 minute walk test to maintain the airways open during the respiratory cycle

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-continuous positive airway pressure (CPAP) device
Description: An enlarged air leak incorporated into the exhalation valve will be positioned between the mask and the CPAP tubing, allowing airflow resistance of the exhalation port to be almost eliminated by increasing its area, thereby virtually cancelling positive pressure. Also an orifice restrictor in the CPAP circuit will be connected between the CPAP unit and the tubing in order to load the blower with the same airflow resistance as in true CPAP.
Study: NCT04024488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TI-CBT Intervention Arm
Description: TI-CBT teaches techniques and ways to manage distress through psychosocial health education, cognitive restructuring, and mastery of trauma, which refers to the process by which survivors of psychological trauma work through the traumatic experience in a meaningful way, and are able to move on with life. TI-CBT addresses both the trauma of learning one has HIV and the trauma associated with managing a chronic and stigmatized illness. The intervention highlights links between HIV and traditional gender roles, gender inequities, and gender based violence. Finally, the relaxation training teaches youth strategies to relax and these are integrated at the beginning and end of each session. TI-CBT Youth and Caregiver Intervention Manuals are distributed to sites for translation, backtranslation, and cultural adaptation in preparation for the Randomized Trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion Control Arm
Description: Each youth discussion control group session will be led by IYL and each caregiver discussion control group will be led by adult study staff. Discussion topics will be selected by youth and caregivers in the group as applicable. Discussion Control group session will take place at a separate time from TI-CBT youth group sessions in attempt to minimize contamination. To note, participant and caregiver group sessions are always held separately.
Study: NCT05469945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compressive garments class II
Description: Daily wearing of compressive garments, especially during prolonged standing upright or strenuous activities.
Study: NCT05276791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMR
Description: Endoscopic mucosal resection, according to standard care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESD
Description: Endoscopic submucosal dissection, according to standard care
Study: NCT04693793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Materials and Janssen Test
Description: Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the Janssen technology. These materials are comprised of a slide deck, a sample test report, and a frequently asked questions (FAQ) sheet.~Intervention 1 participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it during the second round of case simulations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Materials and Janssen Test
Description: Intervention-1- and Intervention-2-arm participants will receive educational materials duplicating what physicians would receive in the real-world market as they adopt the Janssen technology. These materials are comprised of a slide deck, a sample test report, and a frequently asked questions (FAQ) sheet.~Intervention 1 participants only will receive the Janssen test results whether they select it or not, and Intervention 2 participants will receive the Janssen test results only if they select it during the second round of case simulations.
Study: NCT06012136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4004280
Description: VH4004280 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4011499
Description: VH4011499 will be administered.
Study: NCT04909827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D-printed endocrown
Description: pulpotomy and restoration with 3D-printed microfilled hybrid composite endocrown

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zirconia crown
Description: pulpotomy and restoration with prefabricated zirconia crown
Study: NCT05308797

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CASP block
Description: Preoperative, awake, bilateral, ultrasound-guided combine serratus anterior plane block with 30 mL 0.25 % bupivacaine
Study: NCT05509361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK101 injection SC
Description: AK101 is supplied as 135 mg doses, provided in 1 mL prefilled syringes.
Study: NCT05797025

Intervention type: OTHER
Group type: OTHER
Intervention: To assess pressure pain threshold and pinch grip strengths.
Description: To assess pressure pain threshold and pinch grip strengths.

Intervention type: OTHER
Group type: OTHER
Intervention: To assess pressure pain threshold and pinch grip strengths.
Description: To assess pressure pain threshold and pinch grip strengths.
Study: NCT05715619

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VRELysin™
Description: A cocktail of lytic Enterococcus-specific bacteriophages orally administered with sodium bicarbonate solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally administered with sodium bicarbonate solution
Study: NCT06342947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-055009
Description: Softgel Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-055009
Description: Softgel Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-055009
Description: Softgel Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-055009
Description: Softgel Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Softgel Capsule
Study: NCT06268834

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood for zonulin level was drawn from the group.
Description: Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood for zonulin level was drawn from the group.
Description: Serum zonulin levels were determined by taking 5 cc blood from the antebrachial veins of the patients.
Study: NCT05052788

Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: OCT-A detects the motion of blood using intrinsic signals to capture the location of blood vessels. Despite its insensitivity to leakage and the relatively small field of view, the development of OCT-A has the potential to improve our knowledge of the physiology and pathophysiology of the eye.~MRI as a stroke protocol, including T1 and T2 weighted images, diffusion weighted images (DWI), fluid attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and gradient recalled echo (GRE) T2\* weighted images, using a machine 1.5 tesla General Electric machine .

Intervention type: DEVICE
Intervention: Optical coherence tomography angiography
Description: OCT-A detects the motion of blood using intrinsic signals to capture the location of blood vessels. Despite its insensitivity to leakage and the relatively small field of view, the development of OCT-A has the potential to improve our knowledge of the physiology and pathophysiology of the eye.~MRI as a stroke protocol, including T1 and T2 weighted images, diffusion weighted images (DWI), fluid attenuated inversion recovery (FLAIR), magnetic resonance angiography (MRA), and gradient recalled echo (GRE) T2\* weighted images, using a machine 1.5 tesla General Electric machine .
Study: NCT05845281

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bupivakain + deksametazon Adjuvant
Description: In patients who underwent general anesthesia, after the surgical procedure was completed, after sterility was ensured for the ESP group while the patient was in the lateral position for the ESPB procedure, the linear 10-18 MHz USG probe (Esaote MyLab 30, Geneva, Italy) was placed between two transverse processes in the paramedian plane and increased from 1mg/kg to %1 at the T7 level. 20 ml of 0.5 bupivacaine (Buvasin®, Vem, Istanbul, Turkey) + 2% arrhythmic residual SF from 1mg/kg was administered. For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bupivakain + deksametazon Adjuvant
Description: In patients who underwent general anesthesia, after the surgical procedure was completed, after sterility was ensured for the ESP group while the patient was in the lateral position for the ESPB procedure, the linear 10-18 MHz USG probe (Esaote MyLab 30, Geneva, Italy) was placed between two transverse processes in the paramedian plane and increased from 1mg/kg to %1 at the T7 level. 20 ml of 0.5 bupivacaine (Buvasin®, Vem, Istanbul, Turkey) + 2% arrhythmic residual SF from 1mg/kg was administered. For patients in the PCA group, 200 mg of tramadol was placed in 100cc of 0.9% NaCl. Set to PCA device. A 50mg loading dose was administered 10 minutes before the patient was extubated. After extubating, a bolus dose of 20 mg was started, with a 30-minute lock-in time, and an infusion dose of 5mg/hour. The 4-hour maximum limit was set to 200 mg.
Study: NCT05661422

Intervention type: DEVICE
Intervention: RESP™ Biosensor
Description: The RESP Biosensor will be placed on the patient for periodic recording of auscultory sound.